Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Presidential Transition Teams: A Reunion of “Pfizer Pfriends”?

Executive Summary

When Hillary Clinton’s transition team was announced last week, much of the coverage focused (appropriately) on the health care experience of one co-chair, Neera Tanden. But another co-chair, former Michigan Governor Jennifer Granholm, also has an interesting history with the largest US pharma company – and, indirectly, with a member of Donald Trump’s transition team.

You may also be interested in...



Clinton Transition Team Includes Tanden, Underscoring Rx Pricing Focus

Center for American Progress President Neera Tanden has actively advocated Clinton’s position on prescription drug price controls over the past year.

The Real ‘Pill Penalty’: US Biosimilar Law, Not The IRA

Biopharma industry is making some modest headway in quest to change the new US Medicare drug price process to treat drugs and biologics on equal footing. But eliminating the so-called ‘pill penalty’ would not on its own equalize the incentives for small molecule and large molecule R&D.

Medicare Price Negotiation Poses Challenges For Safety Net Providers

New drug pricing program under the Inflation Reduction Act could reduce the value of the 340B drug discount for safety net providers by as much as $1 billion in the first year, an analysis by the 340B Health association suggests.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS119011

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel